Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer.
| Inventor | Institute |
|---|---|
| Vincenzo D'Angiolella | University of Oxford |
| Cat. #: | 153541 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Developmental biology;Genetics |
| Application: | WB |
| Target: | Sufu (UniProt ID: Q9UMX1) |
| Reactivity: | Human ; Mouse |
| Host: | Rabbit |
| Class: | Polyclonal |
| Alternate name: | Suppressor of fused homolog, SUFUH |
|---|---|
| Product description: | Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer. |
| Conjugation: | Unconjugated |
| Immunogen: | Sufu peptide: Hu #347~360: CLESDSSTAIIPHEL (non-phosphorylated) |
| Target background: | Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 2 mg/ml |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.